| 1 |
NCT01483001 |
Completed |
Feasibility Study on Stem Cells Sensitivity Assay |
- Lung Cancer
- Colorectal Cancer
- Breast Cancer
|
- Drug: Cancer Stem Cells Sensitivity Assay
|
Interventional |
Phase 2 |
- Associazione Oncologia Traslazionale
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
|
- Feasibility of the project
- Identification of LC, CRC and BC stem cells
- Sensitivity of LC, CRC and BC stem cells to anti-tumor agents in vitro
- Identification of effective drugs for a specific patient
|
23 |
All |
18 Years and older (Adult, Senior) |
NCT01483001 |
LIVONCO 2011/001
2011-003421-10 |
STELLA |
November 2011 |
September 2012 |
December 2013 |
December 1, 2011 |
January 14, 2015 |
|
- Department of Medical Oncology
Livorno, Italy
|
|
| 2 |
NCT01641003 |
Unknown † |
Isolation and Characterization of Cancer Stem Cells Using iFP Technique |
- Malignant Neoplasm of Breast
- Glioma
- Pancreatic Cancer
|
|
Observational |
|
- Rambam Health Care Campus
|
Other |
- Time Perspective: Prospective
|
- Cancer stem cells percentage
|
15 |
All |
18 Years and older (Adult, Senior) |
NCT01641003 |
cancer stem cells.ctil |
|
July 2012 |
June 2014 |
June 2015 |
July 16, 2012 |
July 16, 2012 |
|
- Rambam Health Care Campus
Haifa, Israel
|
|
| 3 |
NCT02115958 |
Completed |
The Immunotherapy of Nasopharyngeal Cancer Using Cancer Stem Cells Vaccine |
|
- Biological: cancer stem cell vaccine
|
Interventional |
Phase 1
Phase 2 |
- Fuda Cancer Hospital, Guangzhou
- University of Michigan
- Fuda Cancer Hospital, Guangzhou
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Investigator)
- Primary Purpose: Treatment
|
- The primary study purpose to determine the safety of immunization with cancer stem cells vaccine by the number of participants with adverse events
- The secondary objectives are to evaluate vaccine immune responses to the immunizations by the data of body measurements
|
40 |
All |
18 Years to 80 Years (Adult, Senior) |
NCT02115958 |
CLN-001
201401 |
|
March 2014 |
May 2015 |
May 2015 |
April 16, 2014 |
June 3, 2015 |
|
- Biological treatment center in Fuda cancer hospital
Guangzhou, Guangdong, China
|
|
| 4 |
NCT02074046 |
Completed |
Safety Study of Cancer Stem Cell Vaccine to Treat Pancreatic Cancer |
|
- Biological: cancer stem cell vaccine
|
Interventional |
Phase 1
Phase 2 |
- Fuda Cancer Hospital, Guangzhou
- University of Michigan
- Fuda Cancer Hospital, Guangzhou
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Investigator)
- Primary Purpose: Treatment
|
- The primary study purpose to determine the safety of immunization with cancer stem cells vaccine by the number of participants with adverse events
- The secondary objectives are to evaluate vaccine immune responses to the immunizations by the data of body measurements
|
40 |
All |
18 Years to 75 Years (Adult, Senior) |
NCT02074046 |
CLP-001
201401 |
|
February 2014 |
March 2015 |
March 2015 |
February 28, 2014 |
June 3, 2015 |
|
- Biological treatment center in Fuda cancer hospital
Guangzhou, Guangdong, China
|
|
| 5 |
NCT02084823 |
Completed |
Vaccine Therapy in Treating Lung Cancer Patients With Cancer Stem Cells |
|
- Biological: cancer stem cell vaccine
|
Interventional |
Phase 1
Phase 2 |
- Fuda Cancer Hospital, Guangzhou
- University of Michigan
- Fuda Cancer Hospital, Guangzhou
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Investigator)
- Primary Purpose: Treatment
|
- The primary study purpose to determine the safety of immunization with cancer stem cells vaccine by the number of participants with adverse events
- The secondary objectives are to evaluate vaccine immune responses to the immunizations by the data of body measurements
|
40 |
All |
20 Years to 80 Years (Adult, Senior) |
NCT02084823 |
CLL-001
201401 |
|
March 2014 |
October 2014 |
December 2014 |
March 12, 2014 |
June 3, 2015 |
|
- Biological treatment center in Fuda cancer hospital
Guangzhou, Guangdong, China
|
|
| 6 |
NCT02089919 |
Completed |
Cancer Stem Cells Vaccine Therapy in Treating Hepatocellular Cancer Patients |
|
- Biological: cancer stem cell vaccine
|
Interventional |
Phase 1
Phase 2 |
- Fuda Cancer Hospital, Guangzhou
- University of Michigan
- Fuda Cancer Hospital, Guangzhou
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Investigator)
- Primary Purpose: Treatment
|
- The number of participants with adverse events
- The secondary objectives are to evaluate vaccine immune responses to the immunizations by the data of body measurements
|
40 |
All |
18 Years to 75 Years (Adult, Senior) |
NCT02089919 |
CLH-001
201401 |
|
February 2014 |
February 2015 |
February 2015 |
March 18, 2014 |
June 3, 2015 |
|
- Biological treatment center in Fuda cancer hospital
Guangzhou, Guangdong, China
|
|
| 7 |
NCT02176746 |
Completed |
A Phase I/II Study of Active Immunotherapy With Cancer Stem Cells Vaccine for Colorectal Cancer |
|
- Biological: cancer stem cell vaccine
|
Interventional |
Phase 1
Phase 2 |
- Fuda Cancer Hospital, Guangzhou
- University of Michigan
- Fuda Cancer Hospital, Guangzhou
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Investigator)
- Primary Purpose: Treatment
|
- The number of participants with adverse events
- The secondary objectives are to evaluate vaccine immune responses to the immunizations by the data of body measurements
|
40 |
All |
18 Years to 80 Years (Adult, Senior) |
NCT02176746 |
CLC-001 |
CSC |
June 2014 |
May 2015 |
May 2015 |
June 27, 2014 |
June 3, 2015 |
|
- Biological treatment center in Fuda cancer hospital
Guangzhou, Guangdong, China
|
|
| 8 |
NCT01983709 |
Active, not recruiting |
Allogeneic Human Bone Marrow Derived Mesenchymal Stem Cells in Localized Prostate Cancer |
|
- Biological: Allogeneic Human Mesenchymal Stem Cells
|
Interventional |
Phase 1 |
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- To quantify the amount of systemically infused (MSC) DNA relative to recipient DNA at sites of prostate cancer in men with localized adenocarcinoma of the prostate that are scheduled to undergo a prostatectomy
- Feasibility of infusing MSCs into men with localized prostate cancer who plan to undergo a prostatectomy.
- Determine the proportion of MSC to recipient DNA in the peripheral blood at serial time points.
- (and 3 more...)
|
7 |
Male |
18 Years to 100 Years (Adult, Senior) |
NCT01983709 |
J1348
NA_00083720 |
MSC |
October 2013 |
October 2017 |
October 2017 |
November 14, 2013 |
April 28, 2017 |
|
- Johns Hopkins Hospital
Baltimore, Maryland, United States
|
|
| 9 |
NCT02530047 |
Active, not recruiting |
Mesenchymal Stem Cells (MSC) for Ovarian Cancer |
|
- Genetic: MSC-INFβ
- Behavioral: Questionnaires
|
Interventional |
Phase 1 |
- M.D. Anderson Cancer Center
- M.D. Anderson Cancer Center
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Maximum Tolerated Dose (MTD) of Mesenchymal Stem Cells-Interferon-β (MSC-IFNβ)
- Correlation Between the Number of MSC-IFNβ Infused and the Production of Interferon-β and the Number of MSC-IFNβ Detected at the Tumor Sites Via Tumor Biopsy Pre- and Post-Treatment
|
5 |
Female |
18 Years to 90 Years (Adult, Senior) |
NCT02530047 |
2013-0032
CA 136411
NCI-2015-01504 |
|
May 16, 2016 |
May 2019 |
May 2019 |
August 20, 2015 |
December 6, 2017 |
|
- University of Texas MD Anderson Cancer Center
Houston, Texas, United States
|
|
| 10 |
NCT01286883 |
Completed |
Cancer Stem Cell Markers and Prognostic Markers in Circulating Tumor Cells |
|
|
Observational |
|
- Milton S. Hershey Medical Center
|
Other |
- Observational Model: Case-Only
- Time Perspective: Prospective
|
- Primary endpoint: correlation of stem cell markers on CTCs with response to therapy
- Secondary Outcome: Correlation of stem cell markers in primary tumors with stem cell markers in CTCs
|
33 |
All |
18 Years and older (Adult, Senior) |
NCT01286883 |
PSHCI 10-066
PSHMC IRB No. 34902EP |
|
February 2011 |
February 2014 |
September 2014 |
January 31, 2011 |
January 27, 2017 |
|
- Penn State Milton S. Hershey Medical Center
Hershey, Pennsylvania, United States
|
|
| 11 |
NCT01190345 |
Unknown † |
Anti Cancer Stem Cell Activity of Pre-operative Bevacizumab and Chemotherapy in Breast Cancer |
|
- Drug: bevacizumab
- Drug: no bevacizumab
|
Interventional |
Phase 2 |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Measure of the anti-cancer stem cell activity
- Evaluation of the safety of the treatment
- Evaluation of the disease-free survival, recurrence-free survival and overall survival
- Evaluation of the pathological complete response rate
|
75 |
Female |
18 Years and older (Adult, Senior) |
NCT01190345 |
AVASTEM/IPC 2009-001 |
AVASTEM |
May 2010 |
May 2017 |
May 2017 |
August 27, 2010 |
March 20, 2013 |
|
- Jean-Marc EXTRA, MD
Marseille, France - Jean-Yves PIERGA
Paris, France - Hervé CURE
Reims, France
|
|
| 12 |
NCT00429572 |
Completed
Has Results |
Mini-Allogeneic Peripheral Blood Progenitor Cell Transplantation For Recurrent or Metastatic Breast Cancer |
|
- Drug: Fludarabine
- Drug: Melphalan
- Procedure: Stem Cell Infusion
|
Interventional |
Phase 2 |
- M.D. Anderson Cancer Center
- M.D. Anderson Cancer Center
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Number of Participants With Tumor Response
- Overall Survival
- Time to Progressive Disease
- (and 2 more...)
|
19 |
All |
18 Years to 60 Years (Adult) |
NCT00429572 |
DM97-268 |
|
January 1998 |
May 2008 |
May 2008 |
January 31, 2007 |
August 7, 2012 |
July 13, 2011 |
- U.T.M.D. Anderson Cancer Center
Houston, Texas, United States
|
|
| 13 |
NCT02178670 |
Completed |
Safety and Effectivity Immunotherapy to Treat Ovarian Cancer With Cancer Stem Cells Vaccine |
|
|
Interventional |
Phase 1
Phase 2 |
- Fuda Cancer Hospital, Guangzhou
- University of Michigan
- Fuda Cancer Hospital, Guangzhou
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Investigator)
- Primary Purpose: Treatment
|
- The primary study purpose to determine the safety of immunization with cancer stem cells vaccine by the number of participants with adverse events
- The secondary objectives are to evaluate vaccine immune responses to the immunizations by the data of body measurements
|
40 |
Female |
18 Years to 75 Years (Adult, Senior) |
NCT02178670 |
CLO-001
201401 |
|
June 2014 |
April 2015 |
April 2015 |
July 1, 2014 |
June 3, 2015 |
|
- Biological treatment center in Fuda cancer hospital
Guangzhou, Guangdong, China
|
|
| 14 |
NCT01075893 |
Completed |
Changes in Stem Cells of the Colon in Response to Increased Risk of Colorectal Cancer |
|
|
Observational |
|
- Newcastle University
- Northumbria Healthcare NHS Foundation Trust
|
Other |
- Observational Model: Case-Control
- Time Perspective: Prospective
|
- Number of stem cells in the colonic crypt
- Stem cell position in colonic crypt
|
11 |
All |
18 Years to 85 Years (Adult, Senior) |
NCT01075893 |
McCallum-001 |
|
February 2010 |
October 2012 |
October 2012 |
February 25, 2010 |
October 31, 2017 |
|
- Wansbeck General Hospital
Ashington, Tyne & Wear, United Kingdom - North Tyneside Hospital
North Shields, Tyne & Wear, United Kingdom
|
|
| 15 |
NCT00405327 |
Completed |
A Pilot Study of Tumor Cell Vaccine for High-risk Solid Tumor Patients Following Stem Cell Transplantation |
- Sarcoma
- Neuroblastoma
- Wilm's Tumor
|
- Biological: Tumor lysate-pulsed dendritic cell (DC) vaccine
- Other: Hematopoietic stem cell transplantation (HSCT)
|
Interventional |
Phase 2 |
- University of Michigan Cancer Center
- University of Michigan Cancer Center
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- To estimate the rate of immune response of this immunotherapy treatment
- To correlate and characterize the immune response to the clinical response.
- To define immunologic endpoints that can serve as surrogates of clinical response.
|
16 |
All |
up to 30 Years (Child, Adult) |
NCT00405327 |
UMCC 2005.050
GCRC ID # 2191
HUM00002650 |
|
June 2006 |
June 2009 |
June 2010 |
November 30, 2006 |
November 6, 2017 |
|
- University of Michigan, Department of Surgery, Pediatric Section
Ann Arbor, Michigan, United States
|
|
| 16 |
NCT00429507 |
Completed
Has Results |
Sm-EDTMP and Autologous Peripheral Blood Stem Cell Transplantation for Breast Cancer Patients With Bone Only Metastases |
- Breast Cancer
- Bone Metastases
|
- Drug: 153 Sm-EDTMP
- Behavioral: Questionnaire
- Procedure: Stem Cell Transplant
|
Interventional |
Phase 2 |
- M.D. Anderson Cancer Center
- Cytogen Corporation
- M.D. Anderson Cancer Center
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
|
12 |
All |
18 Years to 65 Years (Adult) |
NCT00429507 |
2006-0349
NCI-2010-00573 |
|
March 2007 |
November 2014 |
November 2014 |
January 31, 2007 |
November 24, 2015 |
November 24, 2015 |
- University of Texas MD Anderson Cancer Center
Houston, Texas, United States
|
|
| 17 |
NCT01374841 |
Recruiting |
Hematopoietic Cell Transplantation for Patients With Hematologic Malignancies Using Related, HLA-Haploidentical Donors |
|
- Drug: Cyclophosphamide
- Other: Hematopoietic Stem Cell Transplantation,
|
Interventional |
Phase 2 |
- European Institute of Oncology
- European Institute of Oncology
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Donor engraftment
- Incidence and severity of graft versus host disease
- Non-relapse-related mortality
|
20 |
All |
18 Years to 70 Years (Adult, Senior) |
NCT01374841 |
IEO S513/110
2009-018083-94 |
|
August 2010 |
August 2019 |
December 2019 |
June 16, 2011 |
August 10, 2016 |
|
- European Institute of Oncology
Milan, Italy
|
|
| 18 |
NCT00610415 |
Completed |
Biopsy of Human Tumors for Cancer Stem Cell Characterization: a Feasibility Study |
- Head and Neck Cancer
- Head and Neck Cancers
|
|
Observational |
|
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Quantification of the cancer stem cell population by flow cytometry
|
40 |
All |
18 Years and older (Adult, Senior) |
NCT00610415 |
ENT0023
98543
SU-12142007-934
10514 |
|
December 2007 |
October 2012 |
|
February 8, 2008 |
July 1, 2016 |
|
- Stanford University School of Medicine
Stanford, California, United States
|
|
| 19 |
NCT00003432 |
Terminated |
Immunotherapy in Treating Patients With Metastatic Breast Cancer |
|
- Biological: carcinoembryonic antigen RNA-pulsed DC cancer vaccine
|
Interventional |
Phase 1
Phase 2 |
- Duke University
- National Cancer Institute (NCI)
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Evaluate the ability of active immunotherapy with carcinoembryonic antigen (CEA) RNA pulsed dendritic cells to induce CEA specific T cells in patients with metastatic breast cancer in complete remission following peripheral blood stem cell transplant.
- Determine the clinical efficacy in terms of overall and recurrence free survival of immunotherapy with CEA RNA pulsed dendritic cells in this patients population.
|
4 |
All |
18 Years and older (Adult, Senior) |
NCT00003432 |
2030
IRB 2030
CDR0000066458 |
|
June 1998 |
November 2002 |
November 2002 |
April 25, 2003 |
November 6, 2013 |
|
- Duke Comprehensive Cancer Center
Durham, North Carolina, United States
|
|
| 20 |
NCT02570100 |
Recruiting |
Research and Analysis of the Mechanisms Involved in the Emergence of Breast Cancer Stem Cells (RepriM) |
|
- Procedure: Biological collection
|
Interventional |
Not Applicable |
- Centre Oscar Lambret
- Institut National de la Santé Et de la Recherche Médicale, France
- Institut pour la Recherche sur le Cancer de Lille
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Basic Science
|
- Complete histopathological response
- Evaluation of the expression of genes involved in reprogramming by immunohistochemistry and Reverse Transcription Polymerase Chain Reaction (RT-PCR) according to the rate of CSCs before, during and after chemotherapy.
- Evaluation of relapse-free survival
- Quantification of the frequency of Cancer Stem Cells (CSCs) among the population of Circulating Tumor Cells (CTCs).
|
100 |
Female |
18 Years and older (Adult, Senior) |
NCT02570100 |
RepriM-1407 |
|
April 2015 |
October 2017 |
September 2020 |
October 7, 2015 |
July 28, 2016 |
|
- Centre Oscar Lambret
Lille, France
|
|
| 21 |
NCT00281879 |
Terminated
Has Results |
Donor Stem Cell Transplant or Donor White Blood Cell Infusions in Treating Patients With Hematologic Cancer |
- Chronic Myeloproliferative Disorders
- Leukemia
- Lymphoma
- (and 4 more...)
|
- Biological: anti-thymocyte globulin
- Biological: filgrastim
- Drug: busulfan
- (and 14 more...)
|
Interventional |
Phase 2 |
- OHSU Knight Cancer Institute
- National Cancer Institute (NCI)
- OHSU Knight Cancer Institute
|
Other / NIH |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Number of Participants With Disease Free Survival (DFS).
|
200 |
All |
up to 60 Years (Child, Adult) |
NCT00281879 |
CDR0000452794
P30CA016058
OHSU-TPI-9695-L
OHSU-540 |
|
February 2006 |
February 2008 |
March 2008 |
January 25, 2006 |
September 27, 2017 |
June 19, 2012 |
- OHSU Knight Cancer Institute
Portland, Oregon, United States
|
|
| 22 |
NCT00141765 |
Completed
Has Results |
Study of High-Dose Chemotherapy With Bone Marrow or Stem Cell Transplant for Rare Poor-Prognosis Cancers |
- Wilms Tumor
- Fibrosarcoma
- Carcinoma, Round Cell
- (and 2 more...)
|
- Procedure: Myeloablative Chemotherapy
- Procedure: Stem Cell Rescue
|
Interventional |
Phase 2 |
- University of Michigan Cancer Center
- University of Michigan Cancer Center
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Percent of Participants With Progression Free Survival at 1 Year
|
25 |
All |
up to 21 Years (Child, Adult) |
NCT00141765 |
UMCC 9626
IRB 1996-195 |
|
January 1997 |
December 2008 |
February 2010 |
September 1, 2005 |
June 20, 2014 |
June 20, 2014 |
- The University of Michigan
Ann Arbor, Michigan, United States
|
|
| 23 |
NCT01424865 |
Unknown † |
Cancer Stem Cell Biomarkers as a Predictor of Response to Trastuzumab in Samples From Patients With Breast Cancer Previously Treated in the NSABP-B-31 Trial |
|
- Genetic: fluorescence in situ hybridization
- Other: immunohistochemistry staining method
- Other: immunologic technique
- Other: laboratory biomarker analysis
|
Observational |
|
- NSABP Foundation Inc
- National Cancer Institute (NCI)
|
Other / NIH |
- Observational Model: Case Control
- Time Perspective: Retrospective
|
- ALDH1 expression (percentage of stem cells within the tumor) and association with outcomes regardless of HER2 staining
- HER2 expression in cells with stem cell-like properties as a determinant of aggressiveness and response to trastuzumab in the adjuvant setting
|
1874 |
Female |
18 Years and older (Adult, Senior) |
NCT01424865 |
NSABP B-31 ICSCA
NSABP-B31-ICSC-A |
|
November 2011 |
December 2015 |
|
August 29, 2011 |
May 8, 2015 |
|
|
|
| 24 |
NCT00432094 |
Recruiting |
Autologous Peripheral Blood Stem Cell Transplant for Germ Cell Tumors |
- Childhood Germ Cell Tumor
- Ovarian Cancer
- Teratoma
|
- Drug: carboplatin
- Drug: etoposide
- Drug: ifosfamide
- (and 5 more...)
|
Interventional |
Phase 2 |
- Masonic Cancer Center, University of Minnesota
- Masonic Cancer Center, University of Minnesota
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Overall survival (OS)
- Disease-free survival (DFS)
- Engraftment of platelets
- (and 2 more...)
|
25 |
All |
10 Years to 69 Years (Child, Adult, Senior) |
NCT00432094 |
2006LS032
UMN-MT2005-21
UMN-0608M90586 |
|
December 19, 2006 |
January 2019 |
January 2019 |
February 7, 2007 |
February 13, 2018 |
|
- Masonic Cancer Center at University of Minnesota
Minneapolis, Minnesota, United States
|
|
| 25 |
NCT00002772 |
Terminated |
S9623, Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Women With Breast Cancer |
|
- Biological: filgrastim
- Drug: carboplatin
- Drug: carmustine
- (and 9 more...)
|
Interventional |
Phase 3 |
- Southwest Oncology Group
- National Cancer Institute (NCI)
- Eastern Cooperative Oncology Group
- (and 2 more...)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
|
602 |
Female |
18 Years and older (Adult, Senior) |
NCT00002772 |
CDR0000064747
S9623
U10CA032102 |
|
July 1996 |
February 2004 |
February 2004 |
April 22, 2004 |
January 24, 2013 |
|
- Memorial Sloan-Kettering Cancer Center
New York, New York, United States
|
|
| 26 |
NCT01231022 |
Completed |
Study the Role of Stem Cell in Curing Drug Induced Liver Injury in Metastatic Breast Cancer (MBC) |
- Breast Neoplasms
- Neoplasm Metastasis
|
|
Observational |
|
- Beijing Cancer Hospital
- Beijing Cancer Hospital
|
Other |
- Observational Model: Cohort
- Time Perspective: Cross-Sectional
|
- Protective effection of peripheral hematopoietic stem cell infusion for DILI
- SNPs genotyping associated with Drug Induced Liver Injury
- Change of cytokines
|
52 |
Female |
18 Years to 70 Years (Adult, Senior) |
NCT01231022 |
DILI |
MBC |
August 2010 |
June 2011 |
June 2013 |
November 1, 2010 |
July 29, 2015 |
|
- Beijing Cancer Hospital
Beijing, China
|
|
| 27 |
NCT00020722 |
Terminated
Has Results |
Chemotherapy Followed by Peripheral Stem Cell Transplantation Plus Biological Therapy in Treating Women With Stage IV Breast Cancer |
|
- Biological: therapeutic autologous lymphocytes
- Drug: Ifosfamide, carboplatin, and etoposide (ICE) regimen
- Drug: Cyclophosphamide, Thiotepa, Carboplatin (CTC) or STAMP V (CTC)
- (and 2 more...)
|
Interventional |
Phase 2 |
- Barbara Ann Karmanos Cancer Institute
- National Cancer Institute (NCI)
- Barbara Ann Karmanos Cancer Institute
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Disease-free Survival
- Overall Survival
|
7 |
Female |
18 Years to 120 Years (Adult, Senior) |
NCT00020722 |
CDR0000068707
P30CA022453
WSU-2007-033
RWMC-0634246 |
|
August 2007 |
March 2013 |
March 2013 |
January 27, 2003 |
February 17, 2016 |
March 30, 2015 |
- Barbara Ann Karmanos Cancer Institute
Detroit, Michigan, United States
|
|
| 28 |
NCT01799694 |
Completed |
Stem Cells Treatment for the Local Urinary Incontinence After a Radical Prostate Cancer Surgery (HULPURO) |
|
- Drug: Inject of Autologous Adipose-derived stem cells
|
Interventional |
Phase 2 |
- Instituto de Investigación Hospital Universitario La Paz
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Evaluate the feasibility and security of the autologous e-ASC for the urinary incontinence after a radical prostate cancer surgery
- Quality of life assessment using the SF-12 Questionnaire
- Adverse events
|
10 |
Male |
18 Years and older (Adult, Senior) |
NCT01799694 |
FLPURO-2009-01
2009-016298-14 |
FLPURO |
July 2011 |
February 2013 |
February 2013 |
February 27, 2013 |
March 8, 2013 |
|
- Hospital Universitario La Paz
Madrid, Spain
|
|
| 29 |
NCT00458653 |
Active, not recruiting |
Vaccination With Dendritic Cell/Tumor Fusions With Autologous Stem Cell Transplants in Patients With Multiple Myeloma |
|
- Biological: Dendritic Cell Tumor Fusion
|
Interventional |
Phase 1 |
- Beth Israel Deaconess Medical Center
- Massachusetts General Hospital
- Dana-Farber Cancer Institute
- (and 3 more...)
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- To assess the toxicity associated with vaccination of multiple myeloma patients with dendritic cell/myeloma fusions and GM-CSF prior to stem cell mobilization and following high dose chemotherapy with stem cell rescue.
- To determine whether tumor specific cellular and humoral immunity can be induced by serial vaccination with DC/tumor cell fusions in conjunction with high dose chemotherapy with stem cell rescue
- To determine if vaccination with DC/tumor cell fusions results in clinical disease response in patients with evidence of residual disease post-transplant
- To determine the time to disease progression in this participant population.
|
45 |
All |
18 Years and older (Adult, Senior) |
NCT00458653 |
04-098 |
|
April 2005 |
April 2012 |
June 2018 |
April 11, 2007 |
February 1, 2018 |
|
- Beth Israel Deaconess Medical Center
Boston, Massachusetts, United States - Dana-Farber Cancer Institute/Brigham & Women's Hospital
Boston, Massachusetts, United States - Massachusetts General Hospital
Boston, Massachusetts, United States - Rambam Medical Center
Haifa, Israel
|
|
| 30 |
NCT03407040 |
Enrolling by invitation |
Generation of Cancer Antigen-Specific T-cells From Human Induced Pluripotent Stem Cells (iPSC) for Research and Potential FutureTherapy |
- Gastrointestinal Cancers
- Breast Cancer
- Pancreatic Cancer
- (and 2 more...)
|
|
Observational |
|
- National Cancer Institute (NCI)
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Observational Model: Cohort
- Time Perspective: Retrospective
|
- Production of cancer antigen-specific T cells
- Availability of stored specimens and/or data
|
7000 |
All |
16 Years to 100 Years (Child, Adult, Senior) |
NCT03407040 |
180043
18-C-0043 |
|
January 30, 2018 |
December 31, 2028 |
December 31, 2030 |
January 23, 2018 |
February 14, 2018 |
|
- National Institutes of Health Clinical Center
Bethesda, Maryland, United States
|
|
| 31 |
NCT02063893 |
Completed |
Safety Study of Cancer Stem Cell Vaccinie to Treat Breast Cancer |
|
|
Observational |
|
- Fuda Cancer Hospital, Guangzhou
- University of Michigan
- Fuda Cancer Hospital, Guangzhou
|
Other |
- Observational Model: Case Control
- Time Perspective: Prospective
|
- The primary study purpose to determine the safety of immunization with cancer stem cells vaccinie by the number of participants with adverse events
- The secondary objectives are to evaluate vaccinie immune responses to the immunizations by the data of body measurements
|
40 |
Female |
30 Years to 75 Years (Adult, Senior) |
NCT02063893 |
CLB-001
201401 |
CSC |
January 2014 |
January 2015 |
February 2015 |
February 17, 2014 |
June 3, 2015 |
|
- Biological treatment center in Fuda cancer hospital
Guangzhou, Guangdong, China
|
|
| 32 |
NCT02331134 |
Recruiting |
Tissue and Hematopoietic Stem Cell for Humanized Xenograft Studies in Melanoma and Squamous Head and Neck Cancer |
- Malignant Melanoma
- Head and Neck Cancer
|
|
Interventional |
Not Applicable |
- University of Colorado, Denver
- Karsh Family Research Fund
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Basic Science
|
- Tissue and Hematopoietic Stem Cell Collection
- Identify pharmacodynamic markers
|
20 |
All |
18 Years and older (Adult, Senior) |
NCT02331134 |
14-0842.cc |
|
May 13, 2015 |
March 2018 |
March 2019 |
January 6, 2015 |
March 23, 2018 |
|
- University of Colorado Cancer Center
Aurora, Colorado, United States
|
|
| 33 |
NCT01445132 |
Completed |
Adoptive Cell Therapy for B-Cell Cancers in Patients After Stem Cell Transplantation |
- Chronic Lymphocytic Leukemia
|
- Drug: Allogeneic Cell Therapy w/ Tumor-derived Lypho
|
Interventional |
Phase 1 |
- National Cancer Institute (NCI)
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Primary Purpose: Treatment
|
- To evaluate the feasibility of administering ex-vivo costimulated/expanded tumor-derived lymphocytes (TDL) in patients with persistent or recurrent B-cell lymphoid malignancies (BCL) following treatment with allogeneic hematopoietic stem cell tr...
- To determine the safety of administering TDL in patients with persistent/recurrent BCL following alloHSCT.
|
11 |
All |
18 Years to 75 Years (Adult, Senior) |
NCT01445132 |
070064
07-C-0064 |
|
January 11, 2007 |
April 24, 2013 |
April 24, 2013 |
October 3, 2011 |
February 14, 2018 |
|
- National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States
|
|
| 34 |
NCT00179803 |
Unknown † |
Stem Cell Transplant for High Risk Central Nervous System (CNS) Tumors |
- Glioblastoma
- Astrocytoma
- Pineoblastoma
- (and 2 more...)
|
- Procedure: Stem Cell Transplant
|
Interventional |
Phase 2
Phase 3 |
- Ann & Robert H Lurie Children's Hospital of Chicago
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- To determine if the use of sequential myeloablative chemotherapy with peripheral blood stem cell rescue will increase the overall survival rate in patients with newly diagnosed high risk CNS tumors
- The overall survival and progression free survival in children with recurrent CNS malignancies after obtaining a state of minimum residual disease with submyeloablative chemotherapy, surgery, and/or radiation.
- To determine the progression free survival and overall survival using sequential myeloablative chemotherapy as compared to historical controls with single autologous stem cell rescue following myeloablative chemotherapy.
- (and 2 more...)
|
50 |
All |
18 Months to 25 Years (Child, Adult) |
NCT00179803 |
BMT 0398 |
|
March 1998 |
January 2008 |
|
September 16, 2005 |
March 14, 2011 |
|
- Children's Memorial Hospital
Chicago, Illinois, United States
|
|
| 35 |
NCT01678443 |
Active, not recruiting
Has Results |
Monoclonal Antibody Therapy Before Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoid Malignancies |
- Adult Nasal Type Extranodal NK/T-cell Lymphoma
- Anaplastic Large Cell Lymphoma
- Angioimmunoblastic T-cell Lymphoma
- (and 30 more...)
|
- Biological: indium In 111 anti-CD45 monoclonal antibody BC8
- Radiation: yttrium Y 90 anti-CD45 monoclonal antibody BC8
- Procedure: peripheral blood stem cell transplantation
|
Interventional |
Phase 1 |
- Fred Hutchinson Cancer Research Center
- National Cancer Institute (NCI)
- Fred Hutchinson Cancer Research Center
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Percentage of Participants With Dose Limiting Toxicities (DLT) of Yttrium-90 Anti-CD45
- Overall Response Rate
- Overall Survival
- (and 2 more...)
|
2 |
All |
18 Years and older (Adult, Senior) |
NCT01678443 |
2361.00
NCI-2012-01505
P01CA044991
P30CA015704 |
|
September 1, 1999 |
April 11, 2011 |
July 24, 2019 |
September 5, 2012 |
November 9, 2017 |
November 9, 2017 |
- Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
Seattle, Washington, United States
|
|
| 36 |
NCT00006032 |
Terminated |
Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Women With Metastatic Breast Cancer |
|
- Drug: etoposide
- Drug: ifosfamide
- Drug: topotecan hydrochloride
- Procedure: peripheral blood stem cell transplantation
|
Interventional |
Phase 2 |
- H. Lee Moffitt Cancer Center and Research Institute
- National Cancer Institute (NCI)
- H. Lee Moffitt Cancer Center and Research Institute
|
Other / NIH |
- Primary Purpose: Treatment
|
|
|
Female |
18 Years to 64 Years (Adult) |
NCT00006032 |
MCC-12220
MCC-IRB-5699
NCI-G00-1809 |
|
March 2000 |
April 2001 |
April 2001 |
April 2, 2004 |
December 11, 2012 |
|
- H. Lee Moffitt Cancer Center and Research Institute
Tampa, Florida, United States
|
|
| 37 |
NCT00966498 |
Terminated |
Peripheral Blood Stem Cell Transplant (PBSCT) in Children With High Risk or Recurrent Solid Tumors |
- High Risk Solid Tumors
- Recurrent Solid Tumors
|
- Procedure: Peripheral Blood Stem Cell Transplant
|
Interventional |
Not Applicable |
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- To determine the feasibility and toxicity of tandem high dose chemotherapy and peripheral blood stem cells rescue in patients with high-risk or recurrent solid tumors.
|
3 |
All |
up to 35 Years (Child, Adult) |
NCT00966498 |
1023-2003
PBSCT for ST |
|
May 2003 |
July 2011 |
July 2011 |
August 27, 2009 |
December 11, 2013 |
|
- Children's Healthcare of Atlanta
Atlanta, Georgia, United States - Emory University
Atlanta, Georgia, United States
|
|
| 38 |
NCT00002836 |
Completed |
Filgrastim Plus Chemotherapy Compared With Filgrastim Alone In Treating Women Undergoing Peripheral Stem Cell Transplantation For Breast Cancer |
|
- Biological: Filgrastim (G-CSF)
- Drug: Carmustine
- Drug: Cisplatin
- (and 4 more...)
|
Interventional |
Phase 3 |
- M.D. Anderson Cancer Center
- National Cancer Institute (NCI)
- M.D. Anderson Cancer Center
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Compare Effectiveness of Chemotherapy + Filgrastim to Filgrastim Alone
|
184 |
All |
18 Years to 65 Years (Adult) |
NCT00002836 |
DM95-047
P30CA016672
MDA-DM-95047
NCI-G96-1014
CDR0000065048 |
|
May 1995 |
March 2006 |
March 2006 |
November 24, 2003 |
July 31, 2012 |
|
- University of Texas - MD Anderson Cancer Center
Houston, Texas, United States
|
|
| 39 |
NCT00020410 |
Completed |
Radiolabeled Monoclonal Antibody Followed by Peripheral Stem Cell Transplantation in Treating Patients With Relapsed or Metastatic Breast Cancer |
|
- Biological: filgrastim
- Procedure: peripheral blood stem cell transplantation
- Radiation: yttrium Y 90 monoclonal antibody B3
|
Interventional |
Phase 1 |
- National Cancer Institute (NCI)
- National Cancer Institute (NCI)
|
NIH |
- Primary Purpose: Treatment
|
|
|
All |
18 Years and older (Adult, Senior) |
NCT00020410 |
CDR0000068405
NCI-00-C-0206
NCI-213 |
|
February 2001 |
|
|
January 27, 2003 |
April 30, 2015 |
|
- Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support
Bethesda, Maryland, United States - Center for Cancer Research
Bethesda, Maryland, United States
|
|
| 40 |
NCT00423514 |
Active, not recruiting |
Clofarabine, Melphalan, and Thiotepa Followed By a Donor Stem Cell Transplant in Treating Patients With High-Risk and/or Advanced Hematologic Cancer or Other Disease |
- Graft Versus Host Disease
- Leukemia
- Myelodysplastic Syndromes
|
- Biological: filgrastim
- Drug: clofarabine
- Drug: melphalan
- (and 6 more...)
|
Interventional |
Phase 1
Phase 2 |
- Memorial Sloan Kettering Cancer Center
- National Cancer Institute (NCI)
- Memorial Sloan Kettering Cancer Center
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Relapse of leukemia
- Overall and disease-free survival
- Early post-transplant regimen-related severe morbidity (grade III to IV nonhematologic toxicity) and mortality as measured by the NCI Cancer Therapy Evaluation Program CTCAE v 3.0
|
42 |
All |
up to 54 Years (Child, Adult) |
NCT00423514 |
06-125
MSKCC-06125 |
|
November 2006 |
November 2019 |
November 2019 |
January 18, 2007 |
May 7, 2018 |
|
- Memorial Sloan-Kettering Cancer Center
New York, New York, United States
|
|
| 41 |
NCT00004177 |
Completed |
Radiolabeled Monoclonal Antibody Plus Peripheral Stem Cell Transplantation in Treating Patients With Refractory or Recurrent Ovarian Epithelial Cancer |
|
- Biological: filgrastim
- Procedure: peripheral blood stem cell transplantation
- Radiation: indium In 111 monoclonal antibody MN-14
- Radiation: yttrium Y 90 monoclonal antibody MN-14
|
Interventional |
Phase 1
Phase 2 |
- Garden State Cancer Center at the Center for Molecular Medicine and Immunology
- National Cancer Institute (NCI)
- Garden State Cancer Center at the Center for Molecular Medicine and Immunology
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
|
15 |
Female |
18 Years to 80 Years (Adult, Senior) |
NCT00004177 |
CDR0000067299
R03CA077146
CMMI-C-039A-98
NCI-H99-0044
NCI-V99-1570 |
|
August 1999 |
May 2002 |
|
April 16, 2004 |
June 22, 2011 |
|
- Garden State Cancer Center
Belleville, New Jersey, United States - St. Joseph's Hospital and Medical Center
Paterson, New Jersey, United States - University of Pennsylvania Cancer Center
Philadelphia, Pennsylvania, United States
|
|
| 42 |
NCT02745756 |
Withdrawn |
A Combined Cell Therapy Approach to the Treatment of Neuroblastoma |
- Neuroblastoma
- Neoplasms, Nerve Tissue
|
- Procedure: Autologous Hematopoietic Progenitor Cell Transplant
- Biological: KLH and Tumor Lysate Pulsed DC Vaccine
|
Interventional |
Phase 1 |
- H. Lee Moffitt Cancer Center and Research Institute
- Johns Hopkins All Children's Hospital
- H. Lee Moffitt Cancer Center and Research Institute
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Occurrence of Sufficient Tumor Cell Lysate and Dendritic Cells
- Occurrence of Dendritic Cell Related Adverse Events
|
0 |
All |
up to 21 Years (Child, Adult) |
NCT02745756 |
MCC-17181 |
|
April 14, 2016 |
August 21, 2017 |
August 21, 2017 |
April 20, 2016 |
August 30, 2017 |
|
|
|
| 43 |
NCT02183805 |
Recruiting |
Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Metastatic Triple-negative Breast Cancer |
- Carcinoma Breast Stage IV
|
- Drug: Abraxane,Cyclophosphamide,Carboplatin
|
Interventional |
Phase 2 |
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Progression free Survival
- Overall Survival
|
30 |
Female |
18 Years to 65 Years (Adult) |
NCT02183805 |
SYSUCC-004 |
|
June 2014 |
December 2019 |
December 2019 |
July 8, 2014 |
March 1, 2017 |
|
- Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, China
|
|
| 44 |
NCT00002942 |
Completed |
Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Breast Cancer |
|
- Procedure: autologous bone marrow transplantation
- Procedure: peripheral blood stem cell transplantation
|
Interventional |
Phase 3 |
- Wake Forest University Health Sciences
- National Cancer Institute (NCI)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
|
136 |
All |
18 Years to 60 Years (Adult) |
NCT00002942 |
CDR0000065391
CCCWFU-95496
NCI-G97-1145 |
|
June 1996 |
January 2000 |
December 2003 |
September 3, 2004 |
January 19, 2017 |
|
- Comprehensive Cancer Center of Wake Forest University Baptist Medical Center
Winston-Salem, North Carolina, United States
|
|
| 45 |
NCT00523809 |
Terminated
Has Results |
Allogeneic Hematopoietic Stem Cell Transplantation With Bevacizumab for Advanced Solid Tumor |
- Breast Cancer
- Ovarian Cancer
|
- Drug: Bevacizumab
- Procedure: Allogeneic Hematopoietic Stem Cell Transplantation
- Drug: Fludarabine
- (and 2 more...)
|
Interventional |
Phase 2 |
- M.D. Anderson Cancer Center
- M.D. Anderson Cancer Center
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Progression-free Survival (PFS)
|
5 |
All |
18 Years to 65 Years (Adult) |
NCT00523809 |
2006-0873 |
|
August 2007 |
October 2011 |
October 2011 |
September 3, 2007 |
January 28, 2013 |
January 28, 2013 |
- U.T.M.D. Anderson Cancer Center
Houston, Texas, United States
|
|
| 46 |
NCT00003943 |
Completed |
Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Metastatic Cancer. |
- Carcinoma of Unknown Primary
- Lung Cancer
|
- Biological: filgrastim
- Drug: carboplatin
- Drug: cyclophosphamide
- (and 3 more...)
|
Interventional |
Phase 2 |
- Fox Chase Cancer Center
- National Cancer Institute (NCI)
- Fox Chase Cancer Center
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Determine the one year progression-free survival
- Overall survival; safety of regimen; CR rate; lab correlates; pharmacokinetics
|
3 |
All |
18 Years and older (Adult, Senior) |
NCT00003943 |
CDR0000067136
FCCC-98039
NCI-G99-1535 |
|
September 1998 |
November 2000 |
February 2003 |
May 3, 2004 |
April 17, 2013 |
|
- Johns Hopkins Oncology Center
Baltimore, Maryland, United States - Fox Chase Cancer Center
Philadelphia, Pennsylvania, United States
|
|
| 47 |
NCT00003927 |
Active, not recruiting |
Combination Chemotherapy, Amifostine, and Peripheral Stem Cell Transplantation in Treating Patients With Stage II, Stage III, or Stage IV Breast Cancer |
|
- Biological: filgrastim
- Drug: amifostine trihydrate
- Drug: cyclophosphamide
- (and 3 more...)
|
Interventional |
Phase 1 |
- City of Hope Medical Center
- National Cancer Institute (NCI)
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Feasibility of high dose chemotherapy in advance breast cancer patients.
|
15 |
All |
18 Years to 59 Years (Adult) |
NCT00003927 |
99002
P30CA033572
CHNMC-IRB-99002
ALZA-CHNMC-IRB-99002
NCI-G99-1527
CDR0000067115 |
|
April 22, 1999 |
January 2019 |
January 2019 |
December 11, 2003 |
March 12, 2018 |
|
- Cancer Center and Beckman Research Institute, City of Hope
Duarte, California, United States
|
|
| 48 |
NCT00068523 |
Completed |
Ultraviolet-B Light Therapy and Allogeneic Stem Cell Transplantation in Treating Patients With Hematologic Malignancies |
- Chronic Myeloproliferative Disorders
- Leukemia
- Lymphoma
- (and 3 more...)
|
- Biological: anti-thymocyte globulin
- Drug: cyclophosphamide
- Drug: cyclosporine
- (and 5 more...)
|
Interventional |
Not Applicable |
- Case Comprehensive Cancer Center
- National Cancer Institute (NCI)
- Case Comprehensive Cancer Center
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Study the effectiveness of combining ultraviolet-B light therapy with allogeneic stem cell transplantation in treating patients who have hematologic malignancies.
|
10 |
All |
18 Years and older (Adult, Senior) |
NCT00068523 |
ICC7Y02
P30CA043703
CWRU-ICC-7Y02 |
|
June 2003 |
March 2004 |
|
September 11, 2003 |
June 11, 2010 |
|
- Ireland Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center
Cleveland, Ohio, United States
|
|
| 49 |
NCT00002837 |
Completed |
High-Dose Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Breast Cancer |
|
- Biological: Filgrastim (G-CSF)
- Drug: Cyclophosphamide
- Drug: Doxorubicin Hydrochloride
- (and 2 more...)
|
Interventional |
Phase 1
Phase 2 |
- M.D. Anderson Cancer Center
- National Cancer Institute (NCI)
- Bristol-Myers Squibb
- M.D. Anderson Cancer Center
|
Other / NIH / Industry |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Maximum Tolerated Doses (MTD) of 4 courses Doxorubicin, Paclitaxel, + Cyclophosphamide followed by PBSC and G-CSF Support
|
21 |
All |
15 Years to 60 Years (Child, Adult) |
NCT00002837 |
DM95-156
P30CA016672
MDA-DM-95156
NCI-V96-1017
CDR0000065052 |
|
September 1995 |
January 2002 |
January 2002 |
July 1, 2004 |
July 31, 2012 |
|
- University of Texas - MD Anderson Cancer Center
Houston, Texas, United States
|
|
| 50 |
NCT00510315 |
Active, not recruiting |
Abdominal Obesity and Cardiovascular Risk Factors in Women Who Survived Cancer or a Related Illness Following Total Body Irradiation and Stem Cell Transplant |
- Leukemia
- Hodgkin's Lymphoma
- Non-Hodgkin's Lymphoma
- Myelodysplastic Syndrome
|
- Other: Questionnaires, Laboratory tests, Abdominal MRI
|
Observational |
|
- Memorial Sloan Kettering Cancer Center
- Queen's University, Kingston, Ontario
- Weill Medical College of Cornell University
- Memorial Sloan Kettering Cancer Center
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Explore whether visceral adipose tissue is significantly higher in women who were treated with total body irradiation (TBI) plus stem cell transplant in comparison with women who were not
- Determine the differences in processes of changes, decisional balance for physical activity, body image, mood, and quality of life between the groups
- Determine the correlation between the amount of visceral adipose tissue and fasting levels of triglycerides, LDL, HDL, insulin, glucose, and HOMA-IR in both groups.
- To begin to characterize the psychosocial risk factors of the TBI plus stem cell transplant group, in relation to the comparison group, in order to inform a future targeted intervention to reduce risk.
|
11 |
Female |
18 Years to 49 Years (Adult) |
NCT00510315 |
07-092 |
|
July 2007 |
January 2019 |
January 2019 |
August 2, 2007 |
January 17, 2018 |
|
- Memorial Sloan Kettering Cancer Center
New York, New York, United States
|
|
Create an RSS feed from your search for:
Download the search results for: